FDA approves Retatrutide this year?

2% chance

No trades yet · Ends Jan 1, 2027

Rules

Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or…

Market data references this event on Polymarket. Prices and points here are independent. Not affiliated with Polymarket.

Activity

No trades yet. Be the first.

Comments

Log in to join the conversation.